ProQR Therapeutics (PRQR) News Today $1.88 -0.01 (-0.53%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 5:40 AM | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $2.00July 18, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 200 Day Moving Average of $2.01June 29, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 196,600 shares, a decrease of 18.5% from the May 31st total of 241,200 shares. Based on an average daily trading volume, of 124,600 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.4% of the company's stock are short sold.June 29, 2024 | marketbeat.comStockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to "Hold"StockNews.com upgraded shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday.June 21, 2024 | marketbeat.comStockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to SellStockNews.com downgraded ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.June 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Raised to "Hold" at StockNews.comStockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.June 5, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Rating Lowered to Sell at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.June 5, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50 Day Moving Average of $2.02ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $2.02May 13, 2024 | finance.yahoo.comShareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years agoMay 11, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.May 10, 2024 | markets.businessinsider.comProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial FootingMay 10, 2024 | marketbeat.comProQR Therapeutics' (PRQR) "Buy" Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $2.50 target price on shares of ProQR Therapeutics in a report on Friday.May 9, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comProQR Announces First Quarter 2024 Operating and Financial ResultsMay 8, 2024 | markets.businessinsider.comBuy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical ProspectsMay 8, 2024 | stockhouse.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic DiseasesMay 8, 2024 | finance.yahoo.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesApril 24, 2024 | stockhouse.comProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual MeetingApril 23, 2024 | globenewswire.comProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024April 22, 2024 | finance.yahoo.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 22, 2024 | globenewswire.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 21, 2024 | uk.investing.comProQR retains key patent for RNA editing technologyApril 20, 2024 | stockhouse.comProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP PortfolioApril 19, 2024 | globenewswire.comProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioApril 18, 2024 | marketbeat.comCitigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00Citigroup increased their target price on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a "buy" rating in a research report on Thursday.April 8, 2024 | finance.yahoo.comProQR Therapeutics N.V. (PRQR)March 29, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by AnalystsProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have coveredMarch 18, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of ProQR Therapeutics in a report on Thursday.March 18, 2024 | marketbeat.comChardan Capital Boosts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.50Chardan Capital lifted their price objective on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a "buy" rating in a research note on Thursday.March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic DisordersMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing PlatformMarch 14, 2024 | finance.yahoo.comProQR Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | globenewswire.comProQR Announces Year End 2023 Operating and Financial ResultsMarch 11, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Upgraded by StockNews.com to BuyStockNews.com upgraded ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.February 18, 2024 | finance.yahoo.comPRQR Mar 2024 2.500 callFebruary 16, 2024 | wsj.comProQR Therapeutics N.V.February 15, 2024 | finance.yahoo.comProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingFebruary 8, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by BrokeragesProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned an average recommendation of "Buy" from the five research firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price target among analyFebruary 2, 2024 | marketbeat.comStockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to HoldStockNews.com lowered shares of ProQR Therapeutics from a "buy" rating to a "hold" rating in a report on Friday.January 30, 2024 | stocknews.com4 Biotech Stocks With Massive Buy PotentialJanuary 25, 2024 | marketbeat.comStockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to BuyStockNews.com raised ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.January 19, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024January 19, 2024 | finance.yahoo.comProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024January 15, 2024 | finance.yahoo.comWhile institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the mostJanuary 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Sees Large Decrease in Short InterestProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 680,400 shares, a decrease of 30.6% from the December 15th total of 981,100 shares. Based on an average trading volume of 204,200 shares, the short-interest ratio is currently 3.3 days. Currently, 1.4% of the company's shares are sold short.January 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing PlatformJanuary 5, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing CollaborationJanuary 5, 2024 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR) Dividends: History, Yield and DatesJanuary 5, 2024 | finance.yahoo.comProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here PRQR Media Mentions By Week PRQR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼1.470.62▲Average Medical News Sentiment PRQR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼21▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verve Therapeutics News Today GH Research News Today Entrada Therapeutics News Today Terns Pharmaceuticals News Today Neurogene News Today Mereo BioPharma Group News Today PepGen News Today PureTech Health News Today Annexon News Today Contineum Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
